Document:

Form of No Competition and Non-Disclosure Agreement

 Exhibit 10.19 

 

					
	  
 

	 	 GLOBUS MEDICAL, INC.

NO COMPETITION AND NON-DISCLOSURE AGREEMENT
	 	  
 

 This No Competition and Non-Disclosure Agreement (“NCND Agreement”) is made and entered into between Globus
Medical, Inc., its subsidiaries and divisions including Algea Therapies, Inc. (collectively the “Company”)
and                    (“Employee”)
effective            (“Effective Date”). 

ACKNOWLEDGEMENTS & DEFINITIONS 
  

	A.	The Company is engaged in the design, development, production, distribution and sale of products and services related to the spine (“Products”).

  

	B.	Employee performs services for and on behalf of the Company, either as a direct employee or through an independent service contract, for which Company compensates
Employee, which may include services in connection with promotion or sale of Products. Company desires to employ and/or continue to employ Employee, provided that as an express condition of such employment or continued employment, Employee enters
into this NCND Agreement with Company. In the case of an Employee who is signing this NCND Agreement after the inception of his/her employment relationship with the Company, Employee acknowledges that the Company has provided Employee with valuable
consideration in exchange for signing this NCND Agreement. 

  

	C.	The parties agree that this NCND Agreement is supported by valuable consideration, that mutual promises and obligations have been undertaken by the parties to it, and
that this NCND Agreement is entered into voluntarily by the parties. 

  

	D.	For purposes of this NCND Agreement the Employee’s performance of services and receipt of compensation from the Company will be defined as the Employment Agreement
(the “Employment Agreement”) between the Employee and the Company, whether or not a written employment agreement exists between the Employee and the Company governing said services and compensation. 

 

	E.	For purposes of this NCND Agreement, the term of the Employment Agreement (“Employment Agreement Term”) shall be defined as the time period during which
Employee performs services for or on behalf of the Company. 

  
 1 

	F.	For purposes of this NCND Agreement, the NCND Territory (“NCND Territory”) shall be defined as any geographic area assigned to the Employee within the most
recent 12 months of the Employment Agreement Term. In the event that the Employee has been assigned certain Hospitals (as defined below) and/ or Medical Personnel (as defined below) and not a geographic area within the most recent 12 months of the
Employee Agreement Term, the NCND Territory shall be defined as any Hospitals and/or Medical Personnel to which the Employee was assigned within the most recent 12 months of the Employee Agreement Term. In the event the Employee has not been
assigned to specific Hospitals and/or Medical Personnel or to a specific geographic region within the most recent 12 months of the Employee Agreement Term, the NCND Territory shall be defined as worldwide. 

 

	G.	For purposes of this NCND Agreement, Medical Personnel (“Medical Personnel”) shall be defined as orthopedic surgeons, neurosurgeons, physicians, nurses and
other medical personnel involved in the implantation, purchase or other handling and usage of the Products, including but not limited to employees, agents or persons who control, direct or influence purchasing decisions of any Hospitals.

  

	H.	For purposes of this NCND Agreement, Hospitals (“Hospitals”) shall be defined as hospitals, surgery centers, medical centers and other health care facilities
that purchase Products and the location at which Medical Personnel perform services related to the purchase, implantation or other handling and usage of the Products. 

 

	I.	Employee will have access to confidential, proprietary and trade secret information (“Confidential Information”) belonging to the Company, including
Confidential Information developed by the Employee (see Section 2.2 below). Such Confidential Information includes, but is not limited to: customer lists; product specifications and attributes; pricing information; technology development
plans; forecasts; financial information; sales strategies and techniques; business records; models; prototypes; schematics; manuals; handbooks; literature; vendors; business terms between Company and suppliers; business terms between Company and
Hospitals; business terms between Company and distributors; business terms between Company and Medical Personnel. Employee acknowledges that Company owns such Confidential Information and that Employee has no ownership interest in such Confidential
Information. Furthermore, Employee acknowledges that the disclosure of such Confidential Information to unauthorized third parties, including Competitive Companies (as defined below) would cause great and irreparable harm to the Company.
Furthermore, Employee acknowledges that Company has a legitimate business interest in the protection of the Confidential Information. 

 NO COMPETITION & NO SOLICITATION COVENANT 
  

	1.1	 Competitive Activity. For purposes of this NCND Agreement, Competitive Activity (“Competitive Activity”) shall be defined as
participation in, performance of services for, employment by, ownership of any interest in, or assistance, promotion or organization of, any Competing Company. “Competing Company” is defined as any person, partnership, corporation, firm,
limited liability company, association or other business entity, other than Globus, that manufactures, designs, develops, sells, markets or distributes products or services 

  
 2 

	 	
used in spine surgery; provided that the purchase for investment of not more than five (5%) percent of the total capital stock of such Competing Company whose stock is publicly traded shall
not constitute a Competitive Activity. 

  

	1.2	No Competition Period. For purposes of this NCND Agreement, the No Competition Period (“No Competition Period”) shall be defined as the time period
encompassing both the Employment Agreement Term and the 12-month period immediately after the termination of the Employment Agreement. 

  

	1.3	No Competition or Solicitation Covenant. During the No Competition Period, Employee agrees not to engage in any Competitive Activity for any Competing Company.

 If, during the last year of employment with Company, Employee was engaged exclusively in non-management field
sales activities including selling, soliciting the sale or supporting the sale of Products through contact with Hospitals or Medical Personnel, then Employee’s covenants under this paragraph are as follows: Employee agrees not to engage in any
Competitive Activity with any Hospitals or Medical Personnel during the Employment Agreement Term. In addition, Employee agrees not to engage in any Competitive Activity with any Hospitals or Medical Personal during the No Competition Period in the
NCND Territory. Furthermore, during the No Competition period, Employee agrees not to directly or indirectly, either for the Employee’s benefit or the benefit of another entity, solicit, call on, interfere with, attempt to divert, entice away,
sell to or market to any Hospital in the NCND Territory, or to any Medical Personnel in the NCND Territory who perform any services related to the implantation or other handling and usage of the Products (regardless of whether such services are also
provided by the Medical Personnel outside the NCND Territory). By way of example, if a physician performs services at two different Hospitals, one within and one outside the NCND Territory, the restrictions in this paragraph prohibit the Employee
from directly or indirectly soliciting, calling on, interfering with, or attempting to divert, entice away, sell to or market to the physician at either the Hospital within the NCND Territory or the Hospital outside the NCND Territory. 

 

	1.4	No Solicitation of Company’s Employees or Employees. During the No Competition Period, Employee agrees not to directly or indirectly, either for the
Employee’s benefit or the benefit of another entity, employ or offer to employ in any capacity, contact or recommend for employment with a Competing Company, contact or recommend for the purposes of entering into a contractual relationship with
a Competing Company, or solicit, call on, interfere with, or attempt to divert, or entice away, any individuals who are or were employees, independent contractors, representatives or employees of the Company or of any of the Company’s
distributors at any time within the preceding 12 months. 

 NON-DISCLOSURE COVENANT 

 

	2.1	 Use of Confidential Information. Both during the Employment Agreement Term and after the termination of the Employment Agreement, Employee
agrees not to use any Confidential Information except as required to perform its obligations as an Employee of the Company, or disclose to any individual, corporation, partnership or other entity any Confidential Information belonging to the
Company, unless Employee is required to make such disclosure pursuant to 

  
 3 

	 	
judicial process. Notwithstanding the foregoing, immediately upon receipt of subpoena or other judicial process requiring disclosure of Confidential Information belonging to Company, Employee
shall deliver written notice and a complete copy of such process to the Company and before responding to such process, allow the Company to take such action as they may deem appropriate under the circumstances to protect their interests in the
Confidential Information requested for disclosure. 

  

	2.2	Development of Intellectual Property. Employee may make, discover or develop inventions, ideas, trade secrets, financial materials, computer programs,
discoveries, developmental improvements, know-how, processes and devices related to or used in the conduct of Employee’s performance of services for and on behalf of the Company (“Developments”). The Employee agrees to disclose fully
and promptly to the Company any said Developments. Furthermore, Employee agrees that the Company is the sole and exclusive owner of said Developments; the Employee retains no ownership in said Developments; and said Developments become part of the
Company’s Confidential Information for purposes of this NCND Agreement. Company and Employee agree that if the Developments or any portion thereof are copyrightable, it shall be deemed “work for hire” as such term is defined in the
U.S. Copyright Act. The Employee shall execute and deliver to the Company any and all licenses, applications, assignments and other documents and take any and all actions that the Company may deem necessary or desirable to protect Company’s
ownership rights in said Developments. 

  

	2.3	Handling and Return of Confidential Information. Employee shall not physically or electronically remove or make copies of any Confidential Information owned by
the Company, except as required by the Employee to properly fulfill their responsibilities as an Employee of the Company. Upon the termination of the Employment Agreement, Employee shall immediately return to the Company any and all Confidential
Information in their possession, including any and all copies of said Confidential Information. 

  

	2.4	Fiduciary Duties. Employee agrees that Employee shall treat all Confidential Information entrusted to Employee by Company as a fiduciary, and Employee accepts
and undertakes all the obligations of a fiduciary, including good faith, trust, confidence and candor, to maintain, protect and develop Confidential Information for the benefit of Company. 

 

	2.5	Confidential Information of Others. Employee hereby represents and warrants to the Company that Employee is not bound by any agreement, understanding or
restriction, (including, but not limited to any covenant restricting competition or agreement related to the confidential and proprietary information and trade secrets of any third party), that is inconsistent with or prevents or limits the
Employee’s ability to fulfill his/her obligations under the Employment Agreement. Furthermore, Employee hereby represents and warrants to the Company that the execution and performance of the Employment Agreement will not result in or
constitute a breach of any term or condition of any other agreement the Employee is bound by. In performance of his/her duties and obligations under the Employment Agreement, Employee agrees not to disclose the confidential and proprietary
information or trade secrets of any third party to the Company. 

  
 4 

 REMEDIES 

 

	3.1	Right to Specific Relief. Company and Employee recognize and acknowledge that the limitations set forth in this NCND Agreement are properly required for the
adequate protection of the business of the Company, and that violation of any of the provisions of this NCND Agreement will cause irreparable injury for which money damages are neither adequate nor ascertainable. Accordingly, Company shall have the
right to have the provisions of this NCND Agreement specifically enforced by a court of competent jurisdiction, in addition to any other remedies which Company may have in equity or at law, and Employee hereby consents to the entry of an injunction
or other similar relief without the necessity of posting a bond or other financial insurance. Furthermore, Company shall be entitled to recover its costs and expenses (including reasonable attorneys’ fees) incurred in enforcing its rights under
this NCND Agreement. 

 If a dispute arises under this NCND Agreement, Employee shall have a duty to immediately
notify the Company of the name, address and telephone number of Employee’s legal counsel. In the event Employee fails to provide this information, Employee agrees that the Company may seek a temporary restraining order to enforce the provisions
of this NCND Agreement on an ex parte basis. Employee acknowledges that the Company’s recovery of damages will not be an adequate means to redress a breach of this NCND Agreement. Nothing contained in this paragraph, however, shall
prohibit the Company from pursuing any remedies in addition to injunctive relief, including recovery of damages. 
  

	3.2	Right to Recover Attorneys’ Fees and Costs. (a) If the Company seeks a restraining order, an injunction or any other form of equitable relief, and
recovers any such relief, Company shall be entitled to recover its reasonable attorneys’ fees, court costs, and other costs incurred obtaining that relief (even if other relief sought is denied). (b) If the Company obtains a final judgment
of a court of competent jurisdiction, pursuant to which Employee is determined to have breached his/her obligations under this Agreement, the Company shall be entitled to recover, in addition to any award of damages, its reasonable attorneys’
fees, costs, and expenses incurred by the Company in obtaining such judgment. Any relief awarded under this subparagraph (b) shall be in addition to any other relief awarded under subparagraph (a). The parties agree that the provisions of this
paragraph are reasonable and necessary. 

 OTHER MATTERS 

 

	4.1	Condition to Seeking Subsequent Employment. Employee agrees to show a copy of this NCND Agreement to any Competing Company with whom Employee interviews during
the Employment Agreement Term or with whom Employee interviews within the 12 month period immediately following the termination of the Employment Agreement Term. 

 

	4.2	Entire Agreement. This NCND Agreement constitutes the entire agreement between the parties relating to the specific matters covered by this NCND Agreement and
supersedes all prior agreements, whether written or oral. No modifications or waiver of any part of this NCND Agreement shall be binding upon either party unless in writing. 

  
 5 

	4.3	Waiver. The waiver of a breach of any provision of this NCND Agreement by any party shall not operate or be construed as a waiver of any provision of this NCND
Agreement or consent of any subsequent breach. 

  

	4.4	Severability. If any term or provision of this NCND Agreement shall be determined invalid or unenforceable to any extent or in any application, then the
remainder of this NCND Agreement shall not be affected thereby, and such term or provision shall be deemed modified to the minimum extent necessary to make it consistent with applicable law, except to such extent or in such application, shall not be
affected thereby, every term and provision of this NCND Agreement as so modified if necessary, shall be enforced to the fullest extent and in the broadest application permitted by law. 

 

	4.5	Governing Law. In order to maintain uniformity in the interpretation of this NCND Agreement the parties have expressly agreed that this NCND Agreement, the
parties’ performance hereunder and the relationship between them shall be governed by, construed and enforced in accordance with the laws of the Commonwealth of Pennsylvania, without regard to the principles thereof regarding conflicts of laws.

  

	4.6	Transfer or Assignment; Binding Nature. Company may transfer or assign its rights and obligations pursuant to this NCND Agreement to its successors or assigns.
Employee shall not assign any of his or her rights or delegate any of his or her duties or obligations under this NCND Agreement. This NCND Agreement shall be binding upon and inure to the benefit of the parties hereto and to the Company’s
successors and assigns. 

  

	4.7	Tolling. Employee understands and agrees that in the event of any breach of his/her obligations under paragraphs 1.3 or 1.4 of this NCND Agreement, the No
Competition Period shall be automatically tolled for the amount of time the violation continues. 

 IN WITNESS
WHEREOF, the undersigned have executed this NCND AGREEMENT, intending to be bound under their seals, effective as of the day and year set forth above. 
  

											
	COMPANY:	 		 		 	EMPLOYEE:
					
	By:	 	  
	 		 	By:	 	  

				
	DATE:	 		 		 	DATE:
				
	  
	 		 		 	  

  
 6Third Supplemental Indenture, dated May 1, 2012

 Exhibit 4.1 
 EXECUTION VERSION 
 Merck Sharp & Dohme Corp., formerly known as
Merck & Co., Inc., 
 Schering Corporation, 
 Merck & Co., Inc., formerly known as Schering-Plough Corporation, as a Guarantor 
 and 
 U.S. BANK TRUST NATIONAL ASSOCIATION, 

as Trustee 
 (as
successor to Morgan Guaranty Trust Company of New York) 
  

 
 Third
Supplemental Indenture 
 Dated as of May 1, 2012 
 to 
 Indenture 

Dated as of April 1, 1991 

 SUPPLEMENTAL INDENTURE, dated as of May 1, 2012 (the “Supplemental
Indenture”) among MERCK SHARP & DOHME CORP., formerly known as Merck & Co., Inc., a corporation duly organized and existing under the laws of the State of New Jersey (the “Company”), having its principal
office at One Merck Drive, Whitehouse Station, New Jersey 08889, MERCK & CO., INC., formerly known as Schering-Plough Corporation, a corporation duly organized and existing under the laws of the State of New Jersey (the
“Guarantor”), having its principal office at One Merck Drive, Whitehouse Station, New Jersey 08889 and SCHERING CORPORATION, a corporation duly organized and existing under the laws of the State of New Jersey, having its principal
office at One Merck Drive, Whitehouse Station, New Jersey 08889 (the “Surviving Corporation”), and U.S. BANK TRUST NATIONAL ASSOCIATION, a national banking association duly organized and existing under the laws of the United States
(as successor to Morgan Guaranty Trust Company of New York), as Trustee (the “Trustee”). 
 R E C I T A L S:

 WHEREAS, the Company has heretofore executed and delivered to the Trustee an Indenture, dated as of April 1, 1991, as
supplemented by the First Supplemental Indenture dated as of October 1, 1997 between the Company and the Trustee and the Second Supplemental Indenture dated as of November 3, 2009 between the Company, the Guarantor, and the Trustee (as
supplemented, the “Indenture”). All terms used in this Supplemental Indenture which are defined in the Indenture shall have the same meanings assigned to them in the Indenture. 

WHEREAS, there have previously been issued and are now outstanding under the Indenture, the following series of
Securities: the Company’s 4.375% Notes due 2013, the Company’s 4.75% Notes due 2015, the Company’s 4.000% Notes due 2015, the Company’s 5.000% Notes due 2019, the Company’s 6.3% debentures due 2026, the Company’s 6.4%
debentures due 2028, the Company’s 5.95% debentures due 2028, the Company’s 5 3/4% Notes due 2036, the Company’s 5.76% Notes due 2037, the Company’s 5.850% Notes due 2039, the Company’s floating rate notes due November 27, 2040, the Company’s floating rate
notes due December 21, 2040, the Company’s floating rate notes due December 27, 2040, the Company’s floating rate notes due February 6, 2041, the Company’s floating rate notes due June 21, 2041, the Company’s
floating rate notes due July 18, 2041, the Company’s floating rate notes due December 21, 2041, the Company’s floating rate notes due November 28, 2041, the Company’s floating rate notes due August 22, 2042, the
Company’s floating rate notes due February 18, 2043, and the Company’s floating rate notes due February 12, 2044 (collectively, the “Notes”). 

WHEREAS, the Company is to be merged with and into Surviving Corporation on the date of this Supplemental Indenture (the
“Merger”), with the Surviving Corporation being the surviving Person following the Merger. 
 WHEREAS,
Section 801(1) of the Indenture requires that the Surviving Corporation expressly assume, by supplemental indenture executed and delivered to the Trustee, in form satisfactory to the Trustee, the due and puncutal payment of the principal of and
any premium and interest on all the Notes and the performance or observance of every covenant of the Indenture on the part of the Company to be performed or observed. 

 WHEREAS, Section 901(1) of the Indenture provides that, without the consent of any
Holders, the Company, when authorized by a Board Resolution, and the Trustee, at any time and from time to time, may enter into one or more indentures supplemental thereto, in form satisfactory to the Trustee, to evidence the succession of another
Person to the Company and the assumption by any such successor of the covenants of the Company in the Indenture and in the Notes. 
 WHEREAS, the Company has delivered to the Trustee an Opinion of Counsel pursuant to Section 903 of the Indenture stating that the execution of this Supplemental Indenture is authorized or permitted
by the Indenture. 
 WHEREAS, all things necessary to make this Supplemental Indenture a valid agreement of the Company and the
Successor Corporation, in accordance with its terms, have been done. 
 NOW, THEREFORE, for and in consideration of the premises
and the covenants contained in this Supplemental Indenture, the parties hereto hereby agree for the equal and proportionate benefit of all Holders of the Notes as follows: 
 SECTION 1. For all purposes of this Supplemental Indenture, except as otherwise expressly provided or unless the context otherwise requires, capitalized terms used but not defined herein shall have the
respective meanings ascribed thereto in the Indenture. 
 SECTION 2. The Surviving Corporation hereby assumes the due and
puncutal payment of the principal of and any premium and interest on all the Notes and the performance and observance of every covenant of the Indenture on the part of the Company to be performed or observed. 

SECTION 3. If any provision hereof limits, qualifies or conflicts with another provision hereof which is required to be included in this
Supplemental Indenture by any of the provisions of the Trust Indenture Act, such required provision shall control. 
 SECTION 4.
In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

SECTION 5. Nothing in this Supplemental Indenture, express or implied, shall give to any Person, other than the parties hereto and their
successors under the Indenture and the Holders of the Notes of each series, any benefit or any legal or equitable right, remedy or claim under this Supplemental Indenture. 

 SECTION 6. This Supplemental Indenture supplements the Indenture and shall be a part and
subject to all the terms thereof. Except as supplemented hereby, the Indenture shall continue in full force and effect. 

SECTION 7. This Supplemental Indenture may be executed in any number of counterparts, each of which as so executed shall be deemed to be
an original, but all such counterparts shall together constitute but one and the same instrument. 
 SECTION 8. This
Supplemental Indenture shall be governed by and construed in accordance with the laws of the State of New York. 
 SECTION 9.
This Supplemental Indenture shall be effective and operative concurrently with the completion of the Merger. 
 [SIGNATURE PAGE
FOLLOWS] 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed all as of the day and year first above written. 
  

			
	 MERCK SHARP & DOHME CORP.,
 FORMERLY KNOWN AS MERCK & CO., INC.

		
	By:	 	/s/ Mark E. McDonough
		 	Mark E. McDonough
		 	Vice President and Treasurer

  

	
	Attest:
	
	/s/ Katie Fedosz
	Katie Fedosz
	Assistant Secretary

  

			
	SCHERING CORPORATION
		
	By:	 	/s/ Mark E. McDonough
		 	Mark E. McDonough
		 	Vice President and Treasurer

  

	
	Attest:
	
	/s/ Katie Fedosz
	Katie Fedosz
	Assistant Secretary

  

			
	Acknowledged:
	MERCK & CO., INC, FORMERLY KNOWN AS SCHERING-PLOUGH CORPORATION,
as Guarantor
		
	By:	 	/s/ Mark E. McDonough
		 	Mark E. McDonough
		 	Vice President and Treasurer

  

	
	/s/ Katie Fedosz
	Katie Fedosz
	Assistant Secretary

 [Third Supplemental Indenture Signature Pages] 

 
			
	By:	 	/s/ Patrick Crowley
		 	Patrick J. Crowley
		 	Vice President

  

	
	Attest:
	
	/s/ Beverly A. Freeney
	Beverely A. Freeney
	Vice President

 [Third Supplemental Indenture Signature Pages]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}]]